🏥 Health
21h ago
New First-Line Option Approved in Triple-Negative Breast Cancer
Source ↗
👁 0
💬 0
(MedPage Today) -- The FDA on Friday approved datopotamab deruxtecan (Dato-DXd; Datroway) as a first-line option for unresectable or metastatic triple-negative breast cancer patients ineligible for immunotherapy.
Approval of the Trop2-directed...
Approval of the Trop2-directed...
Comments (0)